Bavencio (avelumab) vs Inlyta (axitinib)

Bavencio (avelumab) is an immunotherapy drug that works by helping the immune system to recognize and attack cancer cells, and it is primarily used to treat Merkel cell carcinoma, urothelial carcinoma, and renal cell carcinoma. In contrast, Inlyta (axitinib) is a targeted therapy known as a tyrosine kinase inhibitor that works by blocking certain proteins that promote tumor growth, and it is specifically indicated for the treatment of advanced renal cell carcinoma. When deciding between the two, a patient’s specific type of cancer, the stage of the disease, previous treatments, and overall health are critical factors to consider, and a healthcare provider can help determine which medication is more appropriate based on these individual circumstances.

Difference between Bavencio and Inlyta

Metric	Bavencio (avelumab)	Inlyta (axitinib)
Generic name	Avelumab	Axitinib
Indications	Metastatic Merkel cell carcinoma, urothelial carcinoma, renal cell carcinoma	Advanced renal cell carcinoma
Mechanism of action	PD-L1 blocking antibody	Tyrosine kinase inhibitor
Brand names	Bavencio	Inlyta
Administrative route	Intravenous	Oral
Side effects	Fatigue, musculoskeletal pain, diarrhea, nausea, infusion-related reactions, rash, decreased appetite	Diarrhea, hypertension, fatigue, decreased appetite, nausea, dysphonia, hypothyroidism, cough, constipation
Contraindications	None known specifically; use caution in patients with pre-existing conditions that can be exacerbated by immune activation	Hypersensitivity to axitinib, risk of severe hemorrhage, uncontrolled hypertension
Drug class	Monoclonal antibody, Immune checkpoint inhibitor	Tyrosine kinase inhibitor
Manufacturer	Merck KGaA and Pfizer	Pfizer

Efficacy

Bavencio (Avelumab) in Combination with Inlyta (Axitinib) for Kidney Cancer

Bavencio (avelumab) is a programmed death ligand-1 (PD-L1) blocking antibody, and Inlyta (axitinib) is a tyrosine kinase inhibitor. Both medications have been studied for their efficacy in treating advanced renal cell carcinoma (RCC), a type of kidney cancer. The combination of these two drugs has been approved for the first-line treatment of patients with advanced RCC based on the results from clinical trials that demonstrated significant improvements in patient outcomes compared to standard therapies.

The efficacy of Bavencio in combination with Inlyta for the treatment of advanced RCC was demonstrated in a multicenter, randomized, open-label trial known as JAVELIN Renal 101. This pivotal trial compared the combination of Bavencio and Inlyta to sunitinib, a standard treatment for advanced RCC. The results showed that the combination significantly improved progression-free survival (PFS) in patients whose tumors expressed PD-L1 and in the overall population, indicating that the combination was effective in delaying the progression of the disease.

Furthermore, the combination of Bavencio and Inlyta also showed an improvement in the overall response rate (ORR), which is the percentage of patients who experienced a significant reduction in tumor size. This improvement in ORR was observed in both the PD-L1 positive population and the overall trial population, suggesting that the combination therapy has a broad application for patients with advanced RCC, regardless of PD-L1 expression status.

While the combination of Bavencio and Inlyta has shown promise in the treatment of advanced RCC, it is important to consider the individual patient's health status, potential side effects, and other treatment options. The decision to use this combination therapy should be made by healthcare professionals in consultation with the patient, taking into account the specific characteristics of the patient's disease and their overall treatment goals. As with any medical treatment, ongoing research and long-term data continue to refine the understanding of the efficacy and safety profile of these medications in the management of kidney cancer.

Regulatory Agency Approvals

Bavencio

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Health Canada
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Therapeutic Goods Administration (TGA), Australia

Inlyta

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA

Access Bavencio or Inlyta today

If Bavencio or Inlyta are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Bavencio

Buy Inlyta

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: